Cerebral falx meningioma

Summary

Cerebral falx meningioma (MONDO:0004422) is a disease. A subtype of anterior cranial fossa meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebral falx meningioma
Mondo ID	MONDO:0004422
DOID	DOID:7986
NCIT	C5267
UMLS	C1333597
MedGen	272627
GARD	0023996
Anatomy (UBERON)	UBERON:0006059
Is cancer (heuristic)	no

Also known as: Falcine meningioma · falx cerebri meningioma · falx cerebri meningioma (disease) · meningioma (disease) of falx cerebri · meningioma of cerebral falx · meningioma of falx cerebri · meningioma of falx of cerebrum · meningioma of the cerebral falx · meningioma of the falx cerebri · meningioma of the falx of the cerebrum

Disease family

This is a subtype of anterior cranial fossa meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › anterior cranial fossa meningioma › cerebral falx meningioma

Related subtypes (2): olfactory groove meningioma, pituitary stalk meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.